Aldemara I Silva1, Victor A D Holanda1, Joaquim G Azevedo Neto1, Edilson D Silva Junior1, Vanessa P Soares-Rachetti1, Girolamo Calo2, Chiara Ruzza2, Elaine C Gavioli3. 1. Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Av. Sen. Salgado Filho, 3000, Lagoa Nova, Natal, 59078-970, Brazil. 2. Department of Medical Sciences, Section of Pharmacology, and National Institute of Neuroscience, University of Ferrara, Ferrara, Italy. 3. Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Av. Sen. Salgado Filho, 3000, Lagoa Nova, Natal, 59078-970, Brazil. egavioli@hotmail.com.
Abstract
RATIONALE: Depression and anxiety frequently co-occur, and this has important clinical implications. Previous studies showed that activation of the nociceptin/orphanin FQ receptor (NOP) elicits anxiolytic effects, while its blockade promotes consistent antidepressant actions. NOP antagonists are effective in reversing footshock-induced depressive-like behaviors, but their effects on stress-induced anxiety are still unclear. OBJECTIVE: This study aimed to investigate the effects of the NOP antagonist SB-612111 on footshock stress-induced anxiety behaviors. METHODS: Male Swiss mice were exposed to inescapable electric footshock stress, and behavioral phenotype was screened based on the ability to escape from footshock (i.e., helpless or non-helpless). Animals were then treated with diazepam (1 mg/kg) and SB-612111 (0.1-10 mg/kg), and their behavior was assessed in the elevated plus-maze (EPM) and open field test. RESULTS: When compared with non-stressed mice, helpless, but not non-helpless, animals displayed significant reductions in the time spent in and entries into open arms in the EPM. Diazepam significantly increased open arms exploration in helpless, non-helpless, and non-stressed mice. However, treatment with the NOP antagonist SB-612111 was inactive in naive mice, while it reversed anxiogenic-related behaviors in helpless mice and increased anxiety states in non-helpless mice. No effects on locomotion were observed. CONCLUSION: Helpless mice displayed increased anxiety compared to non-stressed and non-helpless animals, thus supporting use of this approach as an animal model to investigate anxiety/depression comorbidity. Additionally, SB-612111 modulated anxiety-like behaviors in male mice depending on individual stress susceptibility. Ultimately, NOP antagonists could be useful for treating anxiety in depressed patients.
RATIONALE: Depression and anxiety frequently co-occur, and this has important clinical implications. Previous studies showed that activation of the nociceptin/orphanin FQ receptor (NOP) elicits anxiolytic effects, while its blockade promotes consistent antidepressant actions. NOP antagonists are effective in reversing footshock-induced depressive-like behaviors, but their effects on stress-induced anxiety are still unclear. OBJECTIVE: This study aimed to investigate the effects of the NOP antagonist SB-612111 on footshock stress-induced anxiety behaviors. METHODS: Male Swiss mice were exposed to inescapable electric footshock stress, and behavioral phenotype was screened based on the ability to escape from footshock (i.e., helpless or non-helpless). Animals were then treated with diazepam (1 mg/kg) and SB-612111 (0.1-10 mg/kg), and their behavior was assessed in the elevated plus-maze (EPM) and open field test. RESULTS: When compared with non-stressed mice, helpless, but not non-helpless, animals displayed significant reductions in the time spent in and entries into open arms in the EPM. Diazepam significantly increased open arms exploration in helpless, non-helpless, and non-stressed mice. However, treatment with the NOP antagonist SB-612111 was inactive in naive mice, while it reversed anxiogenic-related behaviors in helpless mice and increased anxiety states in non-helpless mice. No effects on locomotion were observed. CONCLUSION: Helpless mice displayed increased anxiety compared to non-stressed and non-helpless animals, thus supporting use of this approach as an animal model to investigate anxiety/depression comorbidity. Additionally, SB-612111 modulated anxiety-like behaviors in male mice depending on individual stress susceptibility. Ultimately, NOP antagonists could be useful for treating anxiety in depressedpatients.
Authors: A Boom; C Mollereau; J C Meunier; G Vassart; M Parmentier; J J Vanderhaeghen; S N Schiffmann Journal: Neuroscience Date: 1999 Impact factor: 3.590
Authors: Corina O Bondi; Gustavo Rodriguez; Georgianna G Gould; Alan Frazer; David A Morilak Journal: Neuropsychopharmacology Date: 2007-04-04 Impact factor: 7.853
Authors: L Asth; C Ruzza; D Malfacini; I Medeiros; R Guerrini; N T Zaveri; E C Gavioli; G Calo' Journal: Neuropharmacology Date: 2016-02-08 Impact factor: 5.250
Authors: David S Baldwin; Katherine Aitchison; Alan Bateson; H Valerie Curran; Simon Davies; Brian Leonard; David J Nutt; David N Stephens; Sue Wilson Journal: J Psychopharmacol Date: 2013-09-24 Impact factor: 4.153
Authors: Massimo Ubaldi; Nazzareno Cannella; Anna Maria Borruto; Michele Petrella; Maria Vittoria Micioni Di Bonaventura; Laura Soverchia; Serena Stopponi; Friedbert Weiss; Carlo Cifani; Roberto Ciccocioppo Journal: Int J Mol Sci Date: 2021-11-30 Impact factor: 6.208